Objective: This study aimed to develop aptamer-anchored hyperbranched poly(amido amine) (HPAA) for the systemic delivery of and to evaluate its therapeutic potential against bone metastasis of prostate cancer in vivo and in vitro.
Methods: A glutathione (GSH)-responsive cationic HPAA was prepared by the Michael addition reaction. Furthermore, HPAA-PEG was produced by PEGylation, and then the aptamer targeted to prostate-specific membrane antigen (PSMA) was conjugated to the HPAA-PEG. The obtained HPAA-PEG-APT could form nanocomplexes with through electrostatic adsorption.
Results: The results of immunocytochemistry indicated that the complexes could target PSMA-expressing LNCaP cells. The ability of HPAA-PEG-APT to facilitate the delivery of into LNCaP cells was proven, and HPAA-PEG-APT/ demonstrated enhanced antitumor activity, lower cytotoxicity and better biocompatibility in vitro. Moreover, in a tibial injection tumor model, the intravenous injection of the HPAA-PEG-APT/ complex significantly inhibited cancer growth and extended the survival time.
Conclusion: This study provided an aptamer-anchored HPAA-loaded gene system to deliver for better therapeutic efficacy of bone metastasis of prostate cancer.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7533908 | PMC |
http://dx.doi.org/10.2147/IJN.S268398 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!